FY2022 EPS Estimates for ALX Oncology Holdings Inc. Lowered by Analyst (NASDAQ:ALXO)

ALX Oncology Holdings Inc. (NASDAQ:ALXOGet Rating) – Investment analysts at Lifesci Capital cut their FY2022 earnings per share (EPS) estimates for shares of ALX Oncology in a research note issued on Monday, May 9th. Lifesci Capital analyst A. Evertts now anticipates that the company will post earnings of ($2.95) per share for the year, down from their previous estimate of ($2.93).

ALX Oncology (NASDAQ:ALXOGet Rating) last posted its quarterly earnings results on Monday, May 9th. The company reported ($0.60) EPS for the quarter, beating the consensus estimate of ($0.71) by $0.11.

ALXO has been the subject of a number of other research reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of ALX Oncology in a research report on Friday, April 1st. Stifel Nicolaus decreased their price objective on shares of ALX Oncology from $60.00 to $36.00 and set a “buy” rating for the company in a research report on Tuesday, March 1st. Zacks Investment Research upgraded shares of ALX Oncology from a “sell” rating to a “hold” rating in a research report on Tuesday. Finally, HC Wainwright decreased their price objective on shares of ALX Oncology from $100.00 to $80.00 in a research report on Tuesday, March 1st. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, ALX Oncology presently has a consensus rating of “Buy” and a consensus target price of $60.29.

NASDAQ:ALXO opened at $8.58 on Thursday. ALX Oncology has a one year low of $8.47 and a one year high of $81.19. The stock has a market capitalization of $349.04 million, a price-to-earnings ratio of -4.17 and a beta of 2.64. The firm has a fifty day simple moving average of $16.28.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. JPMorgan Chase & Co. grew its stake in ALX Oncology by 21.6% during the 1st quarter. JPMorgan Chase & Co. now owns 19,237 shares of the company’s stock valued at $326,000 after acquiring an additional 3,417 shares in the last quarter. Pier Capital LLC grew its stake in shares of ALX Oncology by 31.0% in the 1st quarter. Pier Capital LLC now owns 394,443 shares of the company’s stock valued at $6,666,000 after buying an additional 93,240 shares during the period. Swiss National Bank grew its stake in shares of ALX Oncology by 8.5% in the 1st quarter. Swiss National Bank now owns 19,200 shares of the company’s stock valued at $324,000 after buying an additional 1,500 shares during the period. IndexIQ Advisors LLC purchased a new stake in shares of ALX Oncology in the 1st quarter valued at approximately $374,000. Finally, Russell Investments Group Ltd. grew its stake in shares of ALX Oncology by 47.2% in the 1st quarter. Russell Investments Group Ltd. now owns 61,000 shares of the company’s stock valued at $1,030,000 after buying an additional 19,570 shares during the period. 89.42% of the stock is owned by institutional investors.

About ALX Oncology (Get Rating)

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors.

Further Reading

Earnings History and Estimates for ALX Oncology (NASDAQ:ALXO)

Receive News & Ratings for ALX Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ALX Oncology and related companies with MarketBeat.com's FREE daily email newsletter.